Clinical trial of trifunctional antibody in hormonally positive her2 patients
not YET RECRUITING, BUT IN THE WORKS:
Fresenius Biotech GmbH, Clinical Development, Frankfurter Ring 193a, 80807 München, Germany Tel: +49 (0)89/30 65 93 17, e-mail: clinicalstudies@fresenius-biotech.com - 4 - Metastatic Breast Cancer Status: Phase II study on the trifunctional antibody ertumaxomab (anti HER2/neu x anti CD3) in patients with hormonal receptor positive and HER/2 expressing (1+ and 2+) advanced or metastatic breast cancer. phase II Her2/neu positive metastatic breast cancer patients not qualifying for treatment with Herceptin and failing anti-hormonal therapies ertumaxomab (anti Her2 x anti CD3) Fresenius Biotech GmbH Tel: +49-(0)89-306 593-17 Email: clinicalstudies@fresenius-biotech.com Not yet recruiting The clinical trials are conducted in collaboration with TRION Pharma. LOOK UP FRESENIUS BIOTECH IN GOOGLE TO SEARCH FOR WEBSITE HOPE THIS HELPS! Lani |
All times are GMT -7. The time now is 06:31 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021